EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways

Raju Ninave iD, Aman Mourya iD, Navnit Prajapati iD

Future Medicinal Chemistry · 03.06.2026 · 18 (11) · 1443-1463

DOI: 10.1080/17568919.2026.2658831 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 21.04.2026. Verfasst von Raju Ninave und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Heterocyclic Compounds, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Heavy Water Board, DAE, Mumbai, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, driving uncontrolled myeloid proliferation. Although BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs) have significantly improved CML management, challenges such as drug resistance, intolerance, and long-term adverse effects persist. To overcome these limitations, recent research has focused on developing next-generation TKIs and alternative molecular scaffolds capable of bypassing resistance mechanisms. Among these, five-membered heterocyclic compounds have gained considerable attention due to their structural diversity, favorable pharmacokinetic properties, and ability to interact with multiple biological targets. Several clinically relevant agents, including dasatinib, ponatinib, and asciminib, incorporate such heterocyclic frameworks, highlighting their therapeutic significance. In addition to direct inhibition of BCR::ABL1, these compounds can modulate key signaling pathways involved in CML progression, such as PI3K/Akt, MAPK, and JAK/STAT. This review explores the chemical diversity, molecular interactions, and therapeutic potential of five-membered heterocyclic compounds in CML. Overall, these scaffolds represent promising candidates for developing more effective and less toxic treatment strategies, improving long-term patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHeterocyclic CompoundsProtein Kinase InhibitorsAntineoplastic AgentsHumansSignal TransductionFusion Proteins, bcr-ablTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ATP-competitive inhibitorsChronic myeloid leukemiafive-membered ringheterocyclic compoundstyrosine kinase inhibitors

Substanzen

Heterocyclic CompoundsProtein Kinase InhibitorsAntineoplastic AgentsFusion Proteins, bcr-ablTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India.

ORCID-Profile: Raju Ninave, Aman Mourya, Navnit Prajapati

Förderung

  • Heavy Water Board, DAE, Mumbai, India

Zitieren

APA

Ninave, R., Mourya, A., & Prajapati, N. (2026). Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways. Future Medicinal Chemistry, 18(11), 1443-1463. https://doi.org/10.1080/17568919.2026.2658831

Vancouver

Ninave R, Mourya A, Prajapati N. Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways. Future Medicinal Chemistry. 2026;18(11):1443-1463. doi:10.1080/17568919.2026.2658831

BibTeX
@article{Ninave2026,
  author = {Ninave, Raju and Mourya, Aman and Prajapati, Navnit},
  title = {Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1443--1463},
  doi = {10.1080/17568919.2026.2658831}
}
Kostenlos starten →